Entera Bio Ltd. (ENTX) Stock Price, News & Analysis

Entera Bio Ltd. (NASDAQ: ENTX) is a clinical-stage biopharmaceutical company focused on the development of orally delivered peptide and protein replacement therapies for significant unmet medical needs. According to the company, its work centers on medical conditions where converting injectable biologic drugs into an oral tablet format has the potential to change how patients are treated. Entera Bio is classified in the biological product manufacturing space and develops product candidates that are intended to be taken as tablets rather than by subcutaneous injection.

The company’s pipeline is built on its proprietary N-Tab™ oral peptide platform. This technology is used to formulate macromolecule therapeutics, including parathyroid hormone (PTH) analogs and other peptides, into mini-tablet or tablet forms designed for oral administration. Entera Bio’s programs target parathyroid hormone PTH(1-34), GLP-1, GLP-2 and oxyntomodulin, with the goal of creating first-in-class oral versions of therapies that are otherwise administered by injection.

Core pipeline and product candidates

Entera Bio’s most advanced product candidate is EB613, described as an oral PTH(1-34) (teriparatide) osteoanabolic tablet. EB613 is being developed as the first oral, once-daily bone-building tablet treatment for postmenopausal women with low bone mineral density (BMD) and high-risk osteoporosis. A placebo-controlled, dose-ranging Phase 2 study in 161 women with postmenopausal osteoporosis or low BMD met primary pharmacodynamic and bone turnover biomarker endpoints and secondary BMD endpoints, and showed increases in lumbar spine, total hip and femoral neck BMD, with no significant safety concerns reported in the cited materials.

Post-hoc analyses of the EB613 Phase 2 trial, presented at scientific meetings, indicated that EB613 produced significant and consistent BMD gains at the spine, femoral neck and hip in both early postmenopausal women (within 10 years of menopause) and in women more than 10 years post-menopause. Additional 3D-DXA analyses suggested significant effects on both trabecular and cortical bone parameters after six months of treatment, with improvements in integral volumetric BMD, trabecular volumetric BMD, cortical thickness and cortical surface BMD compared with placebo.

Regulatory interactions with the U.S. Food and Drug Administration (FDA) are a key element of EB613’s development path. In a written response to a Type A meeting, the FDA agreed that a single multinational, randomized, double-blind, placebo-controlled, 24‑month Phase 3 study in women with postmenopausal osteoporosis, using change in total hip BMD as the primary endpoint and incidence of new or worsening vertebral fractures as a key secondary endpoint, would support a New Drug Application (NDA) for EB613. The company also reports written FDA agreements that dedicated oral carcinogenicity studies and comprehensive nonclinical developmental and reproductive toxicity (DART) studies are not required for EB613 based on existing literature, the reference drug Forteo® and EB613 nonclinical data.

Entera Bio is also working on a Next-Gen EB613 tablet that uses a new generation of the N-Tab™ platform. Preclinical pharmacokinetic data presented in minipigs showed comparable exposure to the current EB613 formulation with a single fixed-dose tablet, supporting continued development as a potential franchise extension.

The EB612 program is being developed as an oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism, a rare endocrine disorder characterized by deficient PTH production, hypocalcemia and hyperphosphatemia. Earlier Phase 2 proof-of-concept work with an unmodified PTH(1-34) analog and an earlier N-Tab® platform generation in 19 patients with hypoparathyroidism demonstrated a reduction in median calcium supplement use while maintaining serum calcium above the lower limit for patients, although that regimen required four-times-daily dosing. More recent preclinical data using a proprietary long-acting PTH analog formulated with the N-Tab® platform showed a markedly longer plasma half-life and sustained calcium elevation for more than three days from a single oral tablet in minipigs, with no adverse events observed in the reported study.

Beyond PTH-based therapies, Entera Bio is collaborating with OPKO Health on oral peptide candidates for intestinal malabsorption syndromes and metabolic diseases. One program combines OPKO’s proprietary long-acting GLP-2 analog (OPK-8801003) with Entera’s N-Tab™ platform to develop what the company describes as a first-in-class oral GLP-2 tablet for patients with short bowel syndrome and related rare malabsorption conditions. Preclinical pharmacokinetic data in minipigs showed an extended plasma half-life, robust oral bioavailability, sustained exposure supporting once-daily dosing, and no observed toxicity.

Another collaboration program focuses on an oral oxyntomodulin (dual GLP-1/glucagon agonist) tablet candidate (OPK-88006) for obesity and metabolic syndromes. Preclinical minipig data presented at an endocrine conference indicated plasma levels consistent with those reported in humans for high-dose injectable semaglutide, supporting the concept of a once-daily oral regimen. Entera Bio also references work on an oral GLP‑1 program within its broader peptide pipeline.

Therapeutic focus areas

Across its portfolio, Entera Bio concentrates on chronic conditions where injectable biologics are standard of care and where an oral alternative could change treatment patterns. The company’s disclosed focus areas include:

• Osteoporosis and low BMD in postmenopausal women at high risk of fracture, addressed by EB613 as an oral osteoanabolic therapy.
• Hypoparathyroidism, targeted by EB612 as an oral PTH(1-34) replacement therapy.
• Short bowel syndrome and rare malabsorption conditions, targeted by the oral GLP-2 analog program in collaboration with OPKO Health.
• Obesity and metabolic disorders, targeted by the oral oxyntomodulin (dual GLP‑1/glucagon) tablet candidate with OPKO.

In multiple communications, Entera Bio emphasizes the large population of women with osteoporosis worldwide, the underutilization of injectable anabolic therapies, and the burden of daily or frequent injections for conditions such as hypoparathyroidism and short bowel syndrome. The company positions its oral tablet candidates as potential injection-free alternatives intended to broaden access and address adherence challenges.

Regulatory and clinical development approach

Entera Bio’s development strategy, as described in its news releases and SEC filings, combines clinical data generation with active regulatory engagement. For EB613, the company highlights alignment with the FDA on the use of total hip BMD as the primary endpoint in a single registrational Phase 3 trial, and references the broader FDA qualification of total hip BMD as a surrogate endpoint for osteoporosis drug development. EB613 Phase 2 data have been presented at meetings such as the American Society for Bone and Mineral Research (ASBMR), the North American Menopause Society (NAMS), and other bone and endocrine conferences.

For its GLP-2 and oxyntomodulin programs with OPKO Health, Entera Bio has reported preclinical pharmacokinetic and pharmacodynamic data at specialized nutrition and endocrine congresses, emphasizing extended half-life, oral bioavailability and exposure profiles consistent with once-daily tablet dosing in animal models. The company notes that these programs are in preclinical or early development stages and that future clinical studies are being planned, subject to regulatory processes.

Public company status and listings

Entera Bio Ltd. is organized under the laws of the State of Israel and reports as a public company with its ordinary shares listed on NASDAQ under the ticker symbol ENTX. The company has also registered warrants on NASDAQ under the symbol ENTXW, with each warrant exercisable for half of an ordinary share at a specified exercise price per share, as referenced in its SEC filings. Entera Bio files periodic and current reports with the U.S. Securities and Exchange Commission, including Forms 8‑K that describe material events such as regulatory milestones and financial results.

Business model characteristics

As a clinical-stage biopharmaceutical company, Entera Bio’s activities and potential future revenue are tied to the research, development and potential commercialization or partnering of its product candidates. The company’s disclosures emphasize:

• Use of the N-Tab™ platform to develop oral formulations of peptide and protein therapeutics.
• Advancement of internal programs such as EB613 and EB612 through clinical trials and regulatory interactions.
• Collaborations with partners like OPKO Health for certain GLP‑2 and oxyntomodulin programs.
• Dependence on regulatory approvals, clinical trial outcomes, intellectual property protection and access to capital, as outlined in its forward-looking statement disclosures.

Entera Bio repeatedly notes in its cautionary statements that it operates as a development-stage company with limited operating history, relies on third parties for clinical trials, and faces risks related to regulatory timelines, market size, competitive position, liquidity and compliance with listing standards.